08:55 EST AnaptysBio (ANAB) trading halted, news pending
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- AnaptysBio’s Strategic Split and Robust Pipeline Justify Buy Rating
- AnaptysBio Reports Q3 2025 Results and Strategic Plans
- AnaptysBio’s Strategic Split and Promising Clinical Developments Drive Buy Rating
- AnaptysBio reports Q3 EPS 52c vs ($1.14) last year
- AnaptysBio announces Phase 2b trial results for rosnilimab in RA